Oncology · Public Health · 2 h ago
Multi-cancer early detection studies leave population-level benefit unresolved
A Nature Medicine commentary highlights complementary evidence from PATHFINDER 2 and NHS-Galleri on multi-cancer early detection test performance, safety and implementation. Demonstrating population-level benefit remains the next challenge; the supplied excerpt contains no quantitative study results.
- Commentary discusses PATHFINDER 2 and NHS-Galleri evidence.
- Population-level benefit remains to be demonstrated.
- Supplied excerpt contains no quantitative study findings.
A Nature Medicine commentary by Catherine R. Marinac, Timothy R. Rebbeck and Elizabeth K. O’Donnell considers evidence from the PATHFINDER 2 and NHS-Galleri studies on multi-cancer early detection tests. The authors describe the studies as providing complementary evidence on clinical performance, safety and implementation, while identifying demonstration of population-level benefit as the next challenge. The supplied excerpt does not report study designs, sample sizes, endpoints or numerical findings, so it cannot support assessment of effect sizes or a change in screening practice. This is commentary rather than a primary study report. Marinac discloses consulting fees from Natera; O’Donnell discloses consulting relationships with several companies, including Natera and Grail, and research funding from Regeneron. Rebbeck declares no competing interests.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Nature Medicine: Some answers, more questions for multi-cancer early detection tests ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.